Clinical characteristics and survival analysis of de novo grade 3 or transformed follicular lymphoma patients.
10.3760/cma.j.issn.0253-2727.2018.09.009
- Author:
Zhi Tao YING
1
;
Hai Ying FENG
;
Lan MI
;
Yu Qin SONG
;
Xiao Pei WANG
;
Wen ZHENG
;
Ning Jing LIN
;
Mai Feng TU
;
Yan XIE
;
Ling Yan PING
;
Chen ZHANG
;
Wei Ping LIU
;
Li Juan DENG
;
Jun ZHU
Author Information
1. Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
- Publication Type:Journal Article
- Keywords:
Cell transformation, neoplastic;
High grade;
Lymphoma, follicular;
Prognosis
- MeSH:
Disease-Free Survival;
Female;
Humans;
Lymphoma, Follicular;
Male;
Neoplasm Recurrence, Local;
Prognosis;
Retrospective Studies;
Survival Analysis
- From:
Chinese Journal of Hematology
2018;39(9):745-750
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the clinical characteristics and survival outcomes of patients with de novo grade 3 or transformed follicular lymphoma (FL). Methods: Fifty-two patients treated at Peking University Cancer Hospital between January 2009 and September 2017 were assessed, including 28 patients with FL 3A grade, 13 patients with FL 3B grade, 11 patients with transformed FL. Baseline characteristics, survival and prognostic factors were analyzed. Results: ① Twenty-six male and 26 female patients were enrolled, including 28 patients with FL 3A grade, 13 patients with FL 3B grade, 11 patients with transformed FL. ②The 3-year progression-free survival (PFS) and overall survival (OS) for the entire cohort were 56.0% and 80.6%, respectively. Patients with international prognostic index (IPI) score 0-1 demonstrated significantly better 3-year PFS (80.3% vs 20.1%; t=18.902, P<0.001) and OS (95.7% vs 57.0%; t=10.406, P<0.001) than patients with IPI score 2-3. Three-year PFS (94.1% vs 37.2% vs 25.2%; P=0.002) and OS (100.0% vs 76.0% vs 59.8%; P=0.020) were also significantly different among patients with FLIPI 1 score 0-1, 2, ≥3. FLIPI 2 score was also identified as a prognostic factor for 3-year PFS (68.4%, 0, 0; P=0.001) and OS(87.5%, 76.2%, 0; P=0.003). ③Multivariate analysis indicated a significant association of PFS (HR=3.536, P=0.015) and OS (HR=15.713, P=0.015) with IPI. FLIPI 2 was associated with OS (score 0-1, HR=0.078, P=0.007; score 2, HR=0.080, P=0.022). Conclusion: De novo grade 3 or transformed FL might be a group of curable disease with current treatment strategies. IPI is still a prognostic tool in this scenario.
